Journal Club Deephak Swaminath. Journal Incidence and predictors of right ventricularpacing- induced cardiomyopathy Shaan Khurshid,MD,* Andrew E.Epstein,MD,FHRS,*

Slides:



Advertisements
Similar presentations
Result of the Pacing to Avoid Cardiac Enlargement (PACE) Trial 1 Institute of Vascular Medicine & Division of Cardiology, Department of Medicine & Therapeutics,
Advertisements

Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.
1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.
for internal use only Evidence Based Medicine The Need to Avoid Unnecessary Ventricular Stimulation.
CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
Purpose To determine whether metoprolol controlled/extended release
Atrial Fibrillation in Patients with Cryptogenic Stroke Gladstone DJ et al. N Engl J Med 2014; 370: Presented by Kris Huston | July 21, 2014.
CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events Purpose To assess the relative efficacy of the antiplatelet drugs clopidogrel.
Copyleft Clinical Trial Results. You Must Redistribute Slides SEISMIC Trial The Safetyand Effects of Implanted (Autologous) Skeletal Myoblasts (MyoCell)
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
Ablation for Paroxysmal Atrial Fibrillation (APAF) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Carlo.
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Sex Differences in Implantable Cardioverter Defibrillator (ICD) Implantation indications and outcomes Guy Amit, MD; Mahmoud Suleiman, MD; Mark Kazatsker,
Prognostic Value of Programmed Electrical Stimulation Among Implantable Cardioverter-Defibrillator Recipients Real-World Data from the Israeli National.
Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
Mr. J is a 70 year old man with an ischemic cardiomyopathy who presents with class III CHF and significant dissatisfaction with his functional capacity.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Heart Failure Ben Starnes MD FACC Interventional Cardiology
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Optimizing Ventricular Pacing in Sinus Node Disease Michael O. Sweeney, MD Brigham and Women’s Hospital Assistant Professor of Medicine Harvard Medical.
Atrial Fibrillation Andreas Stein Robert Smith, M.D. August 11, 2003.
Randomized, double-blind, multicenter, controlled trial.
Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.
May 2005 EP Show The EP Show COMPANION and CARE-HF Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis,
Specialized Atrial Fibrillation Clinic reduces cardiovascular morbidity and mortality in patients with atrial fibrillation Jeroen ML Hendriks, MSc Robert.
Presenter Disclosure Information John F. Beshai, MD RethinQ Trial Results Disclosures Information: The following relationships exist related to this presentation:
Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.
Clinical Symptoms of Atrial Fibrillation in Different Ranges of QRS Duration Burda I.Yu., Yabluchansky N.I. Medical Clinics Chair National University of.
CAST: Cardiac Arrhythmia Suppression Trial Purpose To determine whether therapy with class Ic antiarrhythmics to suppress asymptomatic or mildly symptomatic.
RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.
BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
IRIS Post-hoc Analysis Background IRIS compared the safety and efficacy of early ICD implantation with medical treatment alone in 898 patients at high.
New Application of Biventricular Pacing - Xiamen, 2010
1 ASSESSMENT OF LEFT VENTRICULAR SYSTOLIC DYSFUNCTION BY TISSUE DOPPLER IMAGING SHOWS EVIDENCE OF SUBCLINICAL CARDIOMYOPATHY EARLY AFTER ATHRACYCLINE THERAPY.
CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008 Long-term Cardiac Arrhythmias recorded by Insertable Loop.
Atorvastatin for Reduction of Myocardial Dysrhythmias After Cardiac Surgery Trial Presented at The American College of Cardiology Scientific Sessions March.
Exercise Management Atrial Fibrillation Chapter 9.
INTRODUCTION: INTRODUCTION: implantable cardioverter-defibrillators (ICDs) have clearly demonstrated to terminate an elevated percentage of sustained ventricular.
COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Randomized Trial to Assess Catheter Ablation Versus.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients with Heart Failure with preserved Ejection Fraction Effect of Spironolactone.
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: A randomized comparison ofatrial and dual-chamber.
Left Ventricular Filling Pressure by Doppler Echocardiography in Patients With End-Stage Renal Disease Angela Y-M Wang, Mei Wang, Christopher W-K Lam,
1 Effect of Ramipril on the Incidence of Diabetes The DREAM Trial Investigators N Engl J Med 2006;355 FM R1 윤나리.
Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Influence of Left Ventricular Ejection Fraction.
Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D., Daniel E. Singer, M.D., Werner Hacke, M.D., Ph.D., Gunter Breithardt,
1 Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled.
Flow-Gradient Patterns in Severe Aortic Stenosis With Preserved Ejection Fraction Clinical Characteristics and Predictors of Survival Mackram F. Eleid,
Primary Mitral Regurgitation Degenerative Mitral Valve Disease
Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.
Radiofrequency Ablation as Initial Therapy in Paroxysmal Atrial Fibrillation Jens Cosedis Nielsen, M.D., D.M.Sc., Arne Johannessen, M.D., D.M.Sc., Pekka.
BLOCK HF Study Biventricular versus Right Ventricular Pacing in Patients with Left Ventricular Dysfunction and Atrioventricular Block – Preliminary Results.
David M Kaye MD, PhD on behalf of the REDUCE LAP HF Investigators
– р<0.05 between baseline
Nordic sites Sweden Uppsala University Hospital
Optimal Pacing for Right Ventricular and Biventricular Devices
Cardiac Toxicity on NSABP B-31
ATHENA Trial Presented at Heart Rhythm 2008 in San Francisco, USA
CIBIS II: Cardiac Insufficiency Bisoprolol Study II
ΝΟΣΟΣ ΤΑΧΥΒΡΑΔΥΚΑΡΔΙΑΣ: ΕΜΦΥΤΕΥΣΗ ΒΗΜΑΤΟΔΟΤΗ Η ΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ ; ΓΕΩΡΓΙΟΣ ΣΤΑΥΡΟΠΟΥΛΟΣ ΕΠ.Α ΚΑΡΔΙΟΛΟΓΟΣ ΓΝΘ ΙΠΠΟΚΡΑΤΕΙΟ.
The FAIR-HF Trial Reference
The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter
Presentation transcript:

Journal Club Deephak Swaminath

Journal Incidence and predictors of right ventricularpacing- induced cardiomyopathy Shaan Khurshid,MD,* Andrew E.Epstein,MD,FHRS,* Ralph J.Verdino,MD,* David Lin,MD,FHRS,* Lee R.Goldberg,MD,*† ?Francis E.Marchlinski,MD,FHRS,* David S.Frankel,MD,FHRS*. Heart Rhythm, Vol 11, No 9, September 2014

Circulation Heart failure and echocardiographic changes during long-term follow-up of patients with sick sinus syndrome randomized to single-chamber atrial or ventricular pacing Nielsen JC1, Andersen HR, Thomsen PE, Thuesen L, Mortensen PT, Vesterlund T, Pedersen AK. Nielsen JC1, Andersen HR, Thomsen PE, Thuesen L, Mortensen PT, Vesterlund T, Pedersen AK. Abstract A total of 225 consecutive patients with sick sinus syndrome and intact atrioventricular conduction were randomized to either single-chamber atrial pacing (n = 110) or single- chamber ventricular pacing (n = 115). Clinical assessment included New York Heart Association classification, medication, and M-mode echocardiography before pacemaker implantation, after 3 months, and subsequently once every year. At long-term follow-up (mean, 5.5+/-2.4 years), NYHA class was higher in the ventricular group than in the atrial group (NYHA class I/II/III/IV: 65/44/4/0 versus 84/22/2/1 patients, P=.010). Increase in NYHA class during follow- up was observed in 35 of 113 patients in the ventricular group versus 10 of 109 in the atrial group (P<.0005). Increase in dose of diuretics from randomization to last follow-up was significantly higher in the ventricular group than in the atrial group (21+/-49 versus 8+/-42 mg furosemide/d, P=.033). The left ventricular fractional shortening decreased significantly in the ventricular group (from 0.36+/-0.12 to 0.31+/-0.08, P<.0005) but not in the atrial group (from 0.35+/-0.13 to 0.33+/-0.09, P=.087). The left atrial diameter increased significantly in both treatment groups (ventricular group: from 34+/-7 to 41+/-7 mm, P<.0005; atrial group: from 34+/-6 to 37+/-7 mm, P=.002), but the increase was significantly higher in the ventricular group than in the atrial group (P<.0005).

Literature Search Lancet Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome. Andersen HR1, Thuesen L, Bagger JP, Vesterlund T, Thomsen PE. Andersen HR1, Thuesen L, Bagger JP, Vesterlund T, Thomsen PE. Abstract Prospective randomised trial in 225 consecutive patients with the sick-sinus syndrome, randomised to atrial (n = 110) or ventricular (n = 115) pacing and followed for up to 5 years (mean 40 [SD 18] months). During follow-up, the frequency of atrial fibrillation was higher in the ventricular group, except at the first follow-up at 3 months. Thromboembolic events (stroke or peripheral arterial embolus) occurred in 20 patients in the ventricular group and in 6 patients in the atrial group (p = ). 25 patients died in the ventricular group compared with 21 in the atrial group (p = 0.74).

Literature Search N Engl J Med Biventricular pacing in patients with bradycardia and normal ejection fraction Yu CM1, Chan JY, Zhang Q, Omar R, Yip GW, Hussin A, Fang F, Lam KH, Chan HC, Fung JW. Yu CM1, Chan JY, Zhang Q, Omar R, Yip GW, Hussin A, Fang F, Lam KH, Chan HC, Fung JW. METHODS:In this prospective, double-blind, multicenter study, we randomly assigned 177 patients in whom a biventricular pacemaker had been successfully implanted to receive biventricular pacing (89 patients) or right ventricular apical pacing (88 patients). The primary end points were the left ventricular ejection fraction and left ventricular end-systolic volume at 12 months. RESULTS: At 12 months, the mean left ventricular ejection fraction was significantly lower in the right-ventricular-pacing group than in the biventricular- pacing group (54.8+/-9.1% vs /-7.0%, P<0.001), with an absolute difference of 7.4 percentage points, whereas the left ventricular end-systolic volume was significantly higher in the right-ventricular-pacing group than in the biventricular- pacing group (35.7+/-16.3 ml vs /-10.4 ml, P<0.001), with a relative difference between the groups in the change from baseline of 25% (P<0.001).

Literature search summary Patients exposed to frequent RV pacing develop PICM Does all the patient develop with RV pacing develop PICM ? If a select group is identified then those patients will receive Bivi pacing. Why not every one get Bivi pacing? Cost. Total cost per patient $52,804 vs $40,267(Block-HF trial).

Methods Retrospective study Inclusion Criteria Patients with baseline echocardiogram (LVEF) >50%(6 month).A single-chamber ventricular or dual-chamber pace- maker was implanted; frequent(>20%) RV pacing was present;and a repeat echocardiogram was available atleast 1 year after implantation. Exclusion Criteria: Patients undergoing pulsegenerator change were excluded,as were patients undergoing implantation of implantable cardioverter-defibrillators and single- chamber atrial or biventricular pacemakers.

Data

Data -Definition PICM was defined as a >10% decrease in LVEF, with resultant LVEF of 50%. Medical records were thoroughly searched for alternative causes of cardiomyopathy, including myocardial infarction,myocardial ischemia on stress testing,severe valvular heart disease,atrial arrhythmias with rapidventricular response,frequent(>20%) ventricular prematuredepolarizations(VPDs),and uncontrolled hypertension. When an alternative potential explanation for decrease in LVEF was identified, patients were excluded from further analysis.

Limitation Inclusion Bias To eliminate inclusion bias, all patients would need to undergo surveillance echocardio- grams regardless of clinical need.

Take Home Points PICM maybe more common than previously reported. Men with wider native QRS duration,particularly >115 ms, are at increased risk for the development of PICM pacing upfront, given their high risk for the development of PICM, though the effectiveness and cost of this strategy require prospective study. At the very least, men with wider native QRS duration warrant closer clinical and echocardiographic follow- up. Finally, risk for PICM likely begins below the traditionally accepted cutoff of 40% pacing burden.